These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 20653782

  • 1. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
    Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H, Nagatsuka H, Ohara N, Yoshino T, Takubo K, Vieth M, Tanaka N.
    Histopathology; 2010 Jul; 57(1):90-100. PubMed ID: 20653782
    [Abstract] [Full Text] [Related]

  • 2. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
    Ishimura N, Amano Y, Sanchez-Siles AA, Fukuhara H, Takahashi Y, Uno G, Tamagawa Y, Mishima Y, Yuki T, Ishihara S, Kinoshita Y.
    J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
    [Abstract] [Full Text] [Related]

  • 3. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
    Wilson KT, Fu S, Ramanujam KS, Meltzer SJ.
    Cancer Res; 1998 Jul 15; 58(14):2929-34. PubMed ID: 9679948
    [Abstract] [Full Text] [Related]

  • 4. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer.
    Ling FC, Baldus SE, Khochfar J, Xi H, Neiss S, Brabender J, Metzger R, Drebber U, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM.
    Histopathology; 2007 Jan 15; 50(2):203-9. PubMed ID: 17222248
    [Abstract] [Full Text] [Related]

  • 5. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
    Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat LB, Sanderson IR, Fitzgerald RC.
    Clin Cancer Res; 2004 Jul 15; 10(14):4784-92. PubMed ID: 15269153
    [Abstract] [Full Text] [Related]

  • 6. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
    Beales IL, Ogunwobi O, Cameron E, El-Amin K, Mutungi G, Wilkinson M.
    BMC Cancer; 2007 Jun 08; 7():97. PubMed ID: 17559672
    [Abstract] [Full Text] [Related]

  • 7. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
    Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ.
    Cancer Res; 2000 Oct 15; 60(20):5767-72. PubMed ID: 11059772
    [Abstract] [Full Text] [Related]

  • 8. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
    Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE.
    Am J Gastroenterol; 2001 Apr 15; 96(4):990-6. PubMed ID: 11316217
    [Abstract] [Full Text] [Related]

  • 9. Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma.
    Jiménez P, Piazuelo E, Cebrian C, Ortego J, Strunk M, García-Gonzalez MA, Santander S, Alcedo J, Lanas A.
    Aliment Pharmacol Ther; 2010 Feb 01; 31(3):440-51. PubMed ID: 19843025
    [Abstract] [Full Text] [Related]

  • 10. Aurora kinase A in Barrett's carcinogenesis.
    Rugge M, Fassan M, Zaninotto G, Pizzi M, Giacomelli L, Battaglia G, Rizzetto C, Parente P, Ancona E.
    Hum Pathol; 2010 Oct 01; 41(10):1380-6. PubMed ID: 20656315
    [Abstract] [Full Text] [Related]

  • 11. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
    Majka J, Rembiasz K, Migaczewski M, Budzynski A, Ptak-Belowska A, Pabianczyk R, Urbanczyk K, Zub-Pokrowiecka A, Matlok M, Brzozowski T.
    J Physiol Pharmacol; 2010 Aug 01; 61(4):409-18. PubMed ID: 20814068
    [Abstract] [Full Text] [Related]

  • 12. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ.
    Cancer Epidemiol Biomarkers Prev; 2008 Mar 01; 17(3):727-31. PubMed ID: 18349295
    [Abstract] [Full Text] [Related]

  • 13. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, Pitto F, Nitti D, Celiento T, Zaninotto G, Fiocca R, Rugge M.
    Histopathology; 2012 Nov 01; 61(5):769-76. PubMed ID: 22882541
    [Abstract] [Full Text] [Related]

  • 14. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
    Konturek PC, Kania J, Burnat G, Hahn EG.
    J Physiol Pharmacol; 2006 Dec 01; 57 Suppl 12():15-24. PubMed ID: 17244951
    [Abstract] [Full Text] [Related]

  • 15. Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2.
    Okawa T, Naomoto Y, Nobuhisa T, Takaoka M, Motoki T, Shirakawa Y, Yamatsuji T, Inoue H, Ouchida M, Gunduz M, Nakajima M, Tanaka N.
    Clin Cancer Res; 2005 Nov 15; 11(22):7995-8005. PubMed ID: 16299228
    [Abstract] [Full Text] [Related]

  • 16. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
    Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Weber JL, Russell SE.
    Genes Chromosomes Cancer; 1998 Jan 15; 21(1):49-60. PubMed ID: 9443041
    [Abstract] [Full Text] [Related]

  • 17. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.
    Koss K, Harrison RF, Gregory J, Darnton SJ, Anderson MR, Jankowski JA.
    J Clin Pathol; 2004 Nov 15; 57(11):1156-9. PubMed ID: 15509675
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV.
    Am J Gastroenterol; 2005 Jun 15; 100(6):1257-64. PubMed ID: 15929754
    [Abstract] [Full Text] [Related]

  • 20. Expression of CD44v5 and -v6 in Barrett's carcinoma is not increased compared to that in nondysplastic Barrett's mucosa.
    Menges M, Goebel R, Pueschel W, Zeitz M, Stallmach A.
    Exp Mol Pathol; 2002 Jun 15; 72(3):207-12. PubMed ID: 12009784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.